(GLOBE NEWSWIRE via COMTEX) –Geneva, Switzerland and Boston, MA –October 31, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN),…
Month: October 2018
Q3 2018 ObsEva SA Earnings Conference Call
Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to…
Interview avec Ernest Loumaye, CEO d’ObsEva / Sphère Oct-Dec 2018
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate…
A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer
Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.
ASRM 2018, 6-10 October 2018, Denver, CO
Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA – October 5, 2018– ObsEva SA (NASDAQ: OBSV / SIX:…
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety…